Gazyva™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

Listen to the audio transcription of the CMI leaflet.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Chronic Lymphocytic Leukaemia,Gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL).,Follicular Lymphoma,Gazyva in combination with chemotherapy followed by Gazyva maintenance is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.,Gazyva in combination with bendamustine, followed by Gazyva maintenance, is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond to, or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.,Pre-treatment to reduce the risk of Cytokine Release Syndrome (CRS) induced by glofitamab,Gazyva is indicated as a pre-treatment to reduce the risk of cytokine release syndrome (CRS) induced by glofitamab.,Lupus Nephritis,Gazyva, is indicated for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN) who are receiving standard therapy.

Source: ARTG

• Shelf lifetime is 36 Months
• Store at 2 to 8 degrees Celsius
• Protect from Light; Do not Freeze; Refrigerate

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, concentrated
• Intravenous Infusion
• Clear, colourless to slightly brownish liquid

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 1 vial per pack

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under the following PBS item codes:

• 11460E (Opens in new tab)
• 11456Y (Opens in new tab)
• 13787P (Opens in new tab)
• 12204H (Opens in new tab)
• 13793Y (Opens in new tab)
• 11455X (Opens in new tab)
• 10407R (Opens in new tab)
• 11473W (Opens in new tab)
• 11462G (Opens in new tab)
• 11457B (Opens in new tab)
• 11468N (Opens in new tab)
• 10418H (Opens in new tab)
• 11458C (Opens in new tab)
• 12193R (Opens in new tab)
• 15251Q (Opens in new tab)
• 15265K (Opens in new tab)

Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: Obinutuzumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).